BJS Richard Brady (researchactive.bsky.social) Stephen Chapman Des Winter @ACPGBI Julio Mayol Martyn Evans Frank McDermott Aneel Bhangu The Dukes' Club Miranda Kusters Low LR (<5%) with surg alone for mid rectal T3N0/1 (6-12cm from verge) with clear mrCRM. No info re T3 substage, v few pts with low rectal or N2. V high quality TME (97% mesorect plane). Table 7 important (excludes stage I or >12cm from verge). #colorectalsurgery #radonc #crcsm

Important prospective observational (non-randomised) study in rectal cancer. Devil is in the details x.com/dr_jonathant/s… #colorectalsurgery #radonc #crcsm

Dr. Viktor Grunwald discusses recent real world data in aRCC treatment. VEGFR TKIs Axitinib and Cabozantinib active after IOs. #ESMO18

PURE-01 Prembrolizumab as neoadujant before cystectomy in MIBC: 42%ypT0 Andrea Necchi @ROUMIGUIE Yann NEUZILLET Evanguelos Xylinas Marco Moschini

Surprising data recently presented at ESMO IO showing negative OS effect in patients receiving PPI and checkpoint inhibitors. Although clinical trials now accounting for antibiotics, this PPI effect may merit modification of trials and of clinical practice if confirmed

Improving access to state of the art treatments for lung cancer patients in Australia. Osimertinib listed on the PBS for EGFR T790M+ NSCLC.

#BreastCancer: Changing #TumorCells into #FatCells stops spread medicalnewstoday.com/articles/32418… #Cancer #Oncology

Happy to share our work on survivorship experience in melanoma. It is clearly an increasingly important area in which more knowledge is needed.

Can osteoporosis drug #denosumab improve #cancer #immunotherapy for #kidneycancer? ANZUP #KeyPAD trial is asking this question across Australia. New data shows encouraging outcomes for people with melanoma taking similar treatments bit.ly/2x2nhsf Melanoma and Skin Cancer Trials (MASC Trials)

#UNISON trial testing #immunotherapy in #rare #variant #kidneycancer #GU20 poster today thanks to all pts and their teams!

Prashanth is riding in the Great Cycle Challenge. Support Prashanth's efforts to fight kids' cancer. greatcyclechallenge.com.au/Riders/Prashan…

Combinations of Pembrolizumab/ Keytruda currently being evaluated by Merck. Total 370 trials in 30 tumors, >100 combo trials. #PMWC17

In localized prostate cancer, metastasis-free survival is a surrogate endpoint of overall survival bit.ly/2x0VMx9 #pcsm

#UNISoN trial has now recruited 12 patients and remains ahead of projections, highlighting need for this novel study for those with rare non-clear cell #kidneycancer

#TheraP is a randomised ph2 N=200 #clinicaltrial of 177Lu-PSMA vs cabazitaxel in metCRPC after docetaxel, now recruiting in Australia. Great work by all at ANZUP NHMRC CTC and support from PCFA ANSTO and Endocyte. Info: clinicaltrials.gov/ct2/show/NCT03… anzup.org.au/content.aspx?p… x.com/ANZUPtrials/st…

Congrats Toni Choueiri, MD Dana-Farber on two back-to-back papers in Journal of Clinical Oncology based on METEOR. Data show (1) efficacy in bony metastatic disease and (2) prolongation of time to deterioration (based on PD or sx). Important pieces of data sure to aid in clinical decision-making.

A nice discussion paper on EMT role in cancer Nature Reviews Cancer nature.com/articles/nrc.2…

This year more than 50,000 Australians will be diagnosed with a #rarecancer, which can mean extra challenges when accessing cutting-edge treatments in clinical trials. Learn more in this Background Briefing report which includes Peter Mac's Prof Ben Solomon: radio.abc.net.au/programitem/pg…

Nice paper from Toni Choueiri, MD Dana-Farber mentee Rana McKay UC San Diego Health showing incidence of cardiac mets from RCC. I have seen it! Good news - I have such a pt responding to combo VEGF/IO right now. Javid Moslehi Guillermo de Velasco Dr Raphael B Moreira bit.ly/2E40bGB

Dr Motzer presents the IMmotion 151 data. His conclusions show that these results support the use of Atezolizumab + beva as a first line treatment option in RCC